This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study
Stem Cell Research & Therapy Open Access 29 January 2024
-
Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure
Blood Cancer Journal Open Access 10 December 2023
-
The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
Scientific Reports Open Access 15 October 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.
Gyurkocza B, Sandmaier BM . Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 2014; 124: 344–353.
Rosenberg AR, Syrjala KL, Martin PJ, Flowers ME, Carpenter PA, Salit RB et al. Resilience, health, and quality of life among long-term survivors of hematopoietic cell transplantation. Cancer 2015; 121: 4250–4257.
Flowers ME, Martin PJ . How we treat chronic graft-versus-host disease. Blood 2015; 125: 606–615.
Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267–276.
Atkinson K, Horowitz M, Van Bekkum DW, Gluckman E, Good RA, Jacobsen N et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459–2464.
Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653–660.
Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 2015; 125: 1333–1338.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
Apperley J, Carreras E, Gluckman E, Masszi T . ESH-EBMT Handbook on Haemopoietic Stem Cell Transplantation. EBMT: Paris, France, 2012.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Kaplan EL, Meier P . Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
Frassoni F, Labopin M, Gluckman E, Prentice HG, Gahrton G, Mandelli F et al. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1994; 8: 924–928.
Lee SJ, Klar N, Weeks JC, Antin JH . Predicting costs of stem-cell transplantation. J Clin Oncol 2000; 18: 64–71.
Labopin M, Ruggeri A, Gorin NC, Gluckman E, Blaise D, Mannone L et al. Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France. Haematologica 2014; 99: 535–540.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest
Rights and permissions
About this article
Cite this article
Ruggeri, A., Labopin, M., Ciceri, F. et al. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission. Bone Marrow Transplant 51, 610–611 (2016). https://doi.org/10.1038/bmt.2015.305
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.305
This article is cited by
-
Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study
Stem Cell Research & Therapy (2024)
-
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype
Bone Marrow Transplantation (2024)
-
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Bone Marrow Transplantation (2024)
-
The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
Scientific Reports (2023)
-
Comparison of clinical outcomes between peripheral blood stem cells and peripheral blood stem cells plus bone marrow in myelodysplastic syndrome patients with haploidentical transplantation
Bone Marrow Transplantation (2023)